MYBPHL
protein-codingmyosin binding protein H like, the group of I-set domain containing|Myosin binding proteins
Gene summary
This gene encodes a protein with two immunoglobulin superfamily domains and a fibronectin 3 domain. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2012]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~14.6 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: Unknown
Disease ID:MONDO:0016333
Submitter: Laboratory for Molecular Medicine
This gene-disease relationship has undergone rapid assessment. Classifications are based on preliminary review of gene-disease validity during analysis of genomic sequencing results.
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to MYBPHL variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_001010985.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 21 | 21 | ||||
| missense | 66 | 22 | 88 | |||
| nonsense | 1 | 2 | 3 | |||
| start loss | 0 | |||||
| frameshift | 0 | |||||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 0 | 0 | 67 | 45 | 0 | 112 |
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_001010985.2 | 8 | MANE Select | |
| Ensembl | ENSP00000349678.1 | 8 | MANE Select | |
| RefSeq | NP_001252542.1 | 8 | Standard | |
| Ensembl | ENSP00000638975.1 | 8 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Biological Process
- biological_process
Molecular Function
- molecular_function
- protein binding
Cellular Component
- cellular_component
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000357155
- Coding exons
- 8
- Length
- 14677
- Individuals with no LoFs
- 125365
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 383
- Defined
- 125748
- p
- 0.00152
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.404 | 205 | 222 | 0.924 | 0.0000135 | 2271 |
| Missense (PolyPhen) | 54 | 70.093 | 0.7704 | 789 | ||
| Synonymous | -0.417 | 95 | 90.0 | 1.06 | 0.00000559 | 743 |
| Loss of Function | 2.32 | 7 | 17.5 | 0.401 | 8.29e-7 | 193 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00037 | 0.00037 | rare |
| Latino/Admixed American | 0.00020 | 0.00020 | rare |
| Ashkenazi Jewish | 0.0017 | 0.0017 | notable |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.0031 | 0.0031 | notable |
| European (Non-Finnish) | 0.0021 | 0.0021 | notable |
| South Asian | 0.0010 | 0.0010 | notable |
| Other | 0.0016 | 0.0016 | notable |
dbNSFP Gene Annotations
Source:
Recessive Scores
- pRec
- 0.105
Intolerance Scores
- LoFtool
- 0.670
- RVIS EVS
- 0.6
- RVIS percentile EVS
- 82.83
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.172
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |